argenx NV ADR (ARGX)vsHalozyme Therapeutics Inc (HALO)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
HALO
Halozyme Therapeutics Inc
$107.20
+0.19%
HEALTHCARE · Cap: $12.29B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 219% more annual revenue ($5.32B vs $1.66B). ARGX leads profitability with a 32.3% profit margin vs 24.9%. HALO trades at a lower P/E of 31.9x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
HALO
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Intrinsic value data unavailable for HALO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 288 in profit
Strong operational efficiency at 59.8%
Revenue surging 47.7% year-over-year
Keeps 25 of every $100 in revenue as profit
Earnings expanding 42.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Trading at 85.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 24.9% and operating margin at 59.8%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : HALO
The primary concerns for HALO are P/E Ratio, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 14.95 is elevated, increasing financial risk.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 0.88 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 72/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?